Advertisements



AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals

In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued.....»»

Category: topSource: insidermonkeyMar 20th, 2017

Boston-based Pieris adds AstraZeneca as R&D partner in $45M deal

Shares of Pieris Pharmaceuticals soared on Wednesday after the tiny Boston biotech announced yet another collaboration with a big pharma company, this time grabbing $45 million upfront from AstraZeneca to develop inhalable respiratory disease drugs.....»»

Category: topSource: bizjournalsMay 3rd, 2017

GSK"s new pharma head to join in September after AstraZeneca tussle

LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca......»»

Category: topSource: reutersJun 19th, 2017

Valeant Pharmaceuticals: Bigger is Better

Though the sale of its iNova unit brings Valeant Pharmaceuticals close to meeting its goal of $5 billion in debt reduction by February 2018, the drug maker may need to step up its deal making if it wants to take a real bite out of its debt load......»»

Category: blogSource: barronsJun 8th, 2017

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

AstraZeneca PLC AZN has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grünenthal, a German pharmaceutical company. read more.....»»

Category: blogSource: benzingaJun 8th, 2017

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company. AstraZeneca PLC AZN has in.....»»

Category: topSource: zacksJun 8th, 2017

Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S. Teva .....»»

Category: topSource: zacksMay 16th, 2017

Pieris Pharma stock soars 54% on news of $57.5 mln AstraZeneca deal

Pieris Pharmaceuticals Inc. shares surged as much as 54% in premarket trade Wednesday on news of the company's $57.5 million deal with AstraZen.....»»

Category: topSource: marketwatchMay 3rd, 2017

Nuventra founder inks deal for new venture that could be worth as much as $49 million

A Research Triangle Park-based virtual drug development company 1st Order Pharmaceuticals (1OP) has inked a deal with Canada’s Xenon Pharmaceuticals (Nasdaq: XENE) that could be worth as much as $49 million. 1OP was founded in 2013 by Christoph.....»»

Category: topSource: bizjournalsApr 28th, 2017

Concert rebuffed $250M buyout offer from Vertex before CF drug deal

Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according t.....»»

Category: topSource: bizjournalsMar 24th, 2017

AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application .....»»

Category: topSource: zacksMar 20th, 2017

Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny

Marathon Pharmaceuticals has struck a deal to sell its muscular dystrophy treatment to PTC Therapeutics, two weeks after a group of U.S. senators began scrutinizing the steroidal drug’s pricing......»»

Category: smallbizSource: wsjMar 16th, 2017

$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis

Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, accordi.....»»

Category: topSource: bizjournalsMar 6th, 2017

Pieris Pharmaceuticals" stock soars after exclusive license deal with Japan"s ASKA

Shares of Pieris Pharmaceuticals Inc. soared 16% in premarket trade Monday, after the drug maker announced an exclusive license deal with Japan's ASKA Pharmaceutical Co. Ltd. for the development and comm.....»»

Category: topSource: marketwatchFeb 27th, 2017

MedImmune gets OK from China to pursue arthritis drug in joint venture deal

Gaithersburg-based MedImmune is expanding its footprint in China's drug market after receiving a permit to begin clinical trials there on a biologic therapy for rheumatoid arthritis. MedImmune, which is the R&D arm for London-based AstraZeneca (NYSE:.....»»

Category: topSource: bizjournalsJan 19th, 2017

Japan"s Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

Japan's Takeda Pharmaceutical Co said it has the financial capacity for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal......»»

Category: topSource: foxnewsJan 10th, 2017

Japan"s Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said it has the financial capacity for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal......»»

Category: topSource: reutersJan 9th, 2017

Japanese drugmaker to buy US cancer drug developer

Japanese drugmaker Takeda Pharmaceutical will buy U.S. cancer drug developer Ariad Pharmaceuticals in a $5.2 billion deal that the companies expect to close by the end of February......»»

Category: topSource: moneycentralJan 9th, 2017

Merrimack Pharmaceuticals" Stock Soars On Heavy Volume After Drug Sale Deal

Shares of Merrimack Pharmaceuticals Inc. soared 34% in active premarket trade Monday, after the company announced a deal to sell some drug products to France-based Ipsen SA for up to $1.03 billion......»»

Category: topSource: foxnewsJan 9th, 2017

Merrimack Pharmaceuticals" stock soars on heavy volume after drug sale deal

Shares of Merrimack Pharmaceuticals Inc. soa.....»»

Category: topSource: marketwatchJan 9th, 2017

Japan"s Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

(Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Monday it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline......»»

Category: topSource: reutersJan 9th, 2017